Connect Sign In
FeedbackQuantitative Reverse Transcription Polymerase Chain Reaction
- Use to detect and quantitate CBFB::MYH11 fusion transcripts (type A, D, or E) which result from inv(16) or t(16;16)
- Use to monitor for MRD in patients with a known history of CBFB::MYH11 fusion transcripts (type A, D, or E) from inv(16) or t(16;16) and assess the risk of disease relapse
Testing for CBFB::MYH11 rearrangement may be useful in the evaluation of acute myeloid leukemia (AML) to aid in classification, inform prognosis, and guide therapeutic decision-making. CBFB::MYH11 fusion transcript testing may be used to monitor for minimal residual disease (MRD). This test uses reverse transcription polymerase chain reaction (RT-PCR) to detect if a fusion transcript is present.
Genetics
CBFB::MYH11 fusion transcripts type A, type D, and type E resulting from inv(16) or t(16;16)
Test Interpretation
Analytic Sensitivity
Limit of quantitation: 0.0001 NCN
Limit of detection: 1/10,000 CBFB::MYH11-positive cells. For types A and D, transcripts may be detected below the limit of detection and reported as low positive in cases meeting quality criteria.
Limitations
- Levels can only be reliably compared if the same laboratory and same sample type are used.
- Translocations involving other genes or gene partners will not be detected.
- Uncommon transcripts other than types A, D, or E will not be detected.
References
-
NCCN - acute myeloid leukemia, v5.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: acute myeloid leukemia. Version 5.2026. Updated Jul 2026; accessed Sep 2026.